Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4474 Follow-up 68Ga-DOTATATE PET/CT post resection of small bowel neuroendocrine neoplasia

Introduction: Surgery remains the mainstay of treatment for resectable neuroendocrine neoplasms (NENs). Post resection, guidelines suggest a risk-based approach to surveillance, with 3-6 monthly imaging based on tumour biology. However, there is a paucity of data regarding the timing of surveillance imaging for resected well-differentiated NEN.

Conference:

Presenting Author:

Authors: Sabahi Z, Chan D, Darbhamulla S, Mok C, Samra J,

Keywords: Neuroendocrine, 68Ga-DOTATATE PET/CT, Small bowel,

#4421 Head-to-head comparison of 18F-AlF-NOTA-JR11 PET/MR and 68Ga-DOTATATE PET/CT in patients with neuroendocrine tumours: A prospective study

Introduction: PET/MR combines the molecular advantages of PET with excellent morphologic and anatomic delineation of MRI.18F-AlF-NOTA-JR11, a novel SSTR antagonist with a high affinity for SSTR2, has the potential to perform better than SSTR agonists in neuroendocrine tumour imaging.

Conference:

Presenting Author: Yu J

Authors: Jin X, Xie Q, Lu M, Li J, Yang Z,

Keywords: neuroendocrine tumour, PET/MR, SSTR antagonist, 18F-AlF-NOTA-JR11,

#4340 Predominant volumetric phenotype in dual PET and overall survival in NENs

Introduction: Dual 18F-FDG/68Ga-DOTATATE PET can predict NEN prognosis and guide treatment choice. However, research to date (such as the NEPTET score) has focused on the dual PET phenotype of single-point lesions rather than of the total disease volume.

Conference:

Presenting Author: Chan D

Authors: Chan D, Bernard E, Mokhtar S, Chou A, Gill A,

Keywords: Prognostic biomarker, PET/CT, tumour volume, 18F-FDG, 68Ga-DOTATATE,

#4033 Routine early 68Ga-DOTATATE PET/CT has low diagnostic yield after resection of pancreatic neuroendocrine neoplasms

Introduction: Following resection of primary pancreatic neuroendocrine neoplasm (P-NEN), the reported median disease free survival is ≥4y. 68Ga-DOTATATE PET/CT (DOTA-PET) is widely used for restaging following surgical resection of P-NEN due to a higher sensitivity compared to cross-sectional imaging. We hypothesized that early DOTA-PET has a low yield in detecting recurrent/residual or distant disease in patients following curative-intent surgical resection of non-metastatic localised P-NEN.

Conference:

Presenting Author:

Authors: Singh A, Chan D, Samra J, Pavlakis N, Engel A,

Keywords: Pancreatic NEN, post-resection, restaging, early 68Ga-DOTATATE PET/CT, diagnostic yield,

#3940 Heterogenous uptake of 68Ga-DOTATATE and 18F-FDG in patients with initially diagnosed neuroendocrine tumors: Which patients are suitable for dual-tracer PET imaging?

Introduction: PET scans using FDG and DOTATATE have both been used to study neuroendocrine tumors (NETs).

Conference:

Presenting Author: Yi Z

Authors: Yi Z, Hui W, Ming Gang S, Rong T,

Keywords: 668Ga-DOTATATE, 18F-FDG, neuroendocrine tumor, prognosis,